Analysis of HER2-Low Breast Cancer in Aotearoa New Zealand: A Nationwide Retrospective Cohort Study
The findings suggest a significant proportion of women with invasive breast cancer in New Zealand could benefit from new HER2-targeted treatments. There is a need to standardise HER2 testing to enhance personalised treatment and improve outcomes.
Authors
- Nicholas Knowlton (ORCID: https://orcid.org/0000-0002-7022-3352)
- Annette Lasham (ORCID: https://orcid.org/0000-0002-1084-4261)
- Reenadevi Ramsaroop
- Abbey Wrigley
Institutions
- University of Auckland (NZ)
- Waitemata District Health Board (NZ)
Publication Details
- Journal
- Cancers
- Published
- 2024-09-20
- DOI
- https://doi.org/10.3390/cancers16183204
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- AstraZeneca